Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?

被引:16
|
作者
Piccardo, Arnoldo [1 ]
Puntoni, Matteo [2 ]
Ferrarazzo, Giulia [1 ]
Foppiani, Luca [3 ]
Bottoni, Gianluca [1 ]
Altrinetti, Vania [1 ]
Treglia, Giorgio [4 ,5 ]
Naseri, Mehrdad [1 ]
Dib, Bassam [1 ]
Cabria, Manlio [1 ]
Trimboli, Pierpaolo [4 ,5 ]
Massollo, Michela [1 ]
Giovanella, Luca [4 ,5 ]
机构
[1] Galliera Hosp, Nucl Med Dept, Genoa, Italy
[2] Galliera Hosp, Clin Trial Unit, Off Sci Director, Genoa, Italy
[3] Galliera Hosp, Internal Med, Genoa, Italy
[4] Oncol Inst Southern Switzerland, Dept Nucl Med, Bellinzona, Switzerland
[5] Oncol Inst Southern Switzerland, PET CT Ctr, Bellinzona, Switzerland
关键词
Differentiated thyroid cancer; TSH stimulation; Radioactive remnant ablation; Prognosis; STAGING SYSTEM; DTC PATIENTS; RISK; CARCINOMA; THERAPY; MANAGEMENT; GUIDELINES; LEVEL; TSH;
D O I
10.1007/s00259-018-3955-x
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Current guidelines recommend thyroid hormone withdrawal (THW) of 3-4 weeks before radioiodine remnant ablation (RRA) of differentiated thyroid carcinoma (DTC). We aimed to evaluate (1) the reliability of a shorter THW (i.e., 14 days) to achieve adequate TSH levels (i.e., 30 mU/l), (2) the association between length of THW and response to therapy, and (3) the potential association between pre-ablation TSH levels and patients' outcome. Methods After thyroidectomy, all patients started LT4 therapy, which was subsequently discontinued in order to perform RRA. Patients were broken down into two groups according to the length of THW: group A, 2 weeks of THW, and group B, 3-4 weeks of THW. We used clinical, biochemical, and imaging data to evaluate patients' outcome. By means of univariate and multivariate analysis, including main DTC prognostic factors, we assessed the impact of THW length and TSH levels on patients' outcome. Results We evaluated 222 patients, 85 of whom were treated with RRA after a THW period of 2 weeks (group A). All other 137 patients underwent RRA after 3-4 weeks THW (group B). At the time of RRA all patients presented TSH levels >= 30 MU/l After a median follow-up time of 3.4 years, we found 183 patients (82%) with excellent response to treatment and 39 patients (18%) showing incomplete response. Kaplan-Meier response to therapy curves showed that ablation-Tg, tumor size, and lymph node status were significantly associated with prognosis: no associations were found between THW length, TSH levels, and prognosis. Multivariate Cox model showed that only ablation-Tg was significantly associated with treatment response. Conclusions Prior to RRA, a short 2-week THW is an effective method to stimulate TSH levels. No difference in terms of incomplete response to treatment was observed between DTC patients prepared for RRA with a short THW and those with the long THW.
引用
收藏
页码:1218 / 1223
页数:6
相关论文
共 50 条
  • [1] Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?
    Arnoldo Piccardo
    Matteo Puntoni
    Giulia Ferrarazzo
    Luca Foppiani
    Gianluca Bottoni
    Vania Altrinetti
    Giorgio Treglia
    Mehrdad Naseri
    Bassam Dib
    Manlio Cabria
    Pierpaolo Trimboli
    Michela Massollo
    Luca Giovanella
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 1218 - 1223
  • [2] Radioiodine Thyroid Remnant Ablation after Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal in Patients with High-Risk Differentiated Thyroid Cancer
    Pitoia, Fabian
    Marlowe, Robert J.
    Abelleira, Erika
    Faure, Eduardo N.
    Bueno, Fernanda
    Schwarzstein, Diego
    Julio Lutfi, Ruben
    Niepomniszcze, Hugo
    JOURNAL OF THYROID RESEARCH, 2012, 2012
  • [3] Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta-analysis
    Fu, H.
    Ma, C.
    Tang, L.
    Wu, F.
    Liu, B.
    Wang, H.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 59 (01): : 121 - 128
  • [4] Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy ina real life scenario
    Campenni, A.
    Giovanella, L.
    Pignata, S.
    Mure, M.
    Siracusa, M.
    Cosentino, F.
    Sturiale, L.
    Coppolino, P.
    Ruggeri, M.
    Baldari, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S325 - S326
  • [5] Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy in a real-life scenario
    Campenni, Alfredo
    Giovanella, Luca
    Pignata, Salvatore A.
    Violi, Maria A.
    Siracusa, Massimiliano
    Alibrandi, Angela
    Moleti, Mariacarla
    Amato, Ernesto
    Ruggeri, Rosaria M.
    Vermiglio, Francesco
    Baldari, Sergio
    NUCLEAR MEDICINE COMMUNICATIONS, 2015, 36 (11) : 1100 - 1106
  • [6] Different Radioiodine Dose for Remnant Thyroid Ablation in Patients With Differentiated Thyroid Cancer A Meta-analysis
    Song, Xinghua
    Meng, Zhaowei
    Jia, Qiang
    Zhang, Linlin
    Xu, Ke
    Tan, Jian
    Zhang, Guizhi
    Zheng, Wei
    Li, Xue
    Zhang, Jianping
    CLINICAL NUCLEAR MEDICINE, 2015, 40 (10) : 774 - 779
  • [7] Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients
    Castagna, M. G.
    Cantara, S.
    Pacini, F.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2016, 39 (10) : 1087 - 1094
  • [8] Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients
    M. G. Castagna
    S. Cantara
    F. Pacini
    Journal of Endocrinological Investigation, 2016, 39 : 1087 - 1094
  • [9] Therapeutic efficacies of remnant ablation and radioiodine adjuvant therapy in differentiated thyroid cancer
    Liu, Yanlin
    Huang, Shuhui
    Li, Xiaohui
    Tian, Tian
    Huang, Rui
    ENDOCRINE, 2025, 87 (02) : 734 - 743
  • [10] Metastatic differentiated thyroid cancer in paediatric patients - radioiodine treatment after thyroid hormone withdrawal or rhTSH stimulation
    Handkiewicz-Junak, D.
    Kropinska, A.
    Ledwon, A.
    Roskosz, J.
    Kula, D.
    Kluczewska, A.
    Olczyk, T.
    Paliczka, E.
    Puch, Z.
    Jarzab, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S120 - S121